Otonomy is expected to release their data from the Ménière’s trial in the second half of 2017; analysts predict the drug could generate peak sales of $603 million, according to the article. Auris’ data is expected in 2018 and could generate peak sales of $250 million, according to Reuters.
To read the full article, please visit the Reuters website here.
Hearing Review has reported on Auris Medical Holding’s peer-reviewed research on AM-101 as well as the 2016 results of Otonomy’s clinical trials of OTO-104 to treat Ménière’s disease; there are currently no FDA-approved drugs to treat Ménière’s disease.
Source: Reuters, Hearing Review